Drug cuts breast cancer cases

Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53% compared with women who took a placebo, according to a study published in the Lancet. The results of the IBIS II trial, funded by Cancer Research UK and led by Queen Mary University of London, could offer a new option for preventing breast cancer in high risk post-menopausal women which is more effective than tamoxifen and has fewer side-effects.

The study looked at almost 4,000 postmenopausal women at high risk of breast cancer with half being given 1mg of anastrozole daily and half given a placebo. In the five years of follow up 40 women in the anastrozole group developed breast cancer compared to 85 women placebo group.

Professor Jack Cuzick, lead researcher and head of Queen Mary University of London's Centre for Cancer Prevention, said: "This research is an exciting development in breast cancer prevention. We now know anastrozole should be the drug of choice when it comes to reducing the risk of breast cancer in postmenopausal women with a family history or other risk factors for the disease. This class of drugs is more effective than previous drugs such as tamoxifen and crucially, it has fewer side effects.

"Unpleasant side effects such as acute aches and pains have often been associated with oestrogen depriving drugs. However, in this study, the reported side effects were only slightly higher than in the placebo arm. This means most symptoms were not drug related, and the concern about side effects for this type of drug may have been overstated in the past.

"Our priority now is ensuring that as many women as possible can benefit from these new findings. Prevention is an important tool in the fight against breast cancer and we strongly urge the National Institute for Health and Care Excellence (NICE) to consider adding anastrozole to their recommended drugs for women who are predisposed to developing breast cancer. By including this drug in their clinical guidelines, more women will benefit from this important advancement in preventive medicine."

Many breast cancers are fuelled by the hormone oestrogen. Anastrozole works by preventing the body from making oestrogen and has for many years been used to treat postmenopausal women with oestrogen receptor positive breast cancer.

Women were judged to be at high risk of breast cancer if they fulfilled one of the following criteria: having two or more blood relatives with breast cancer, having a mother or sister who developed breast cancer before the age of 50, and having a mother or sister who had breast cancer in both breasts, or having certain high risk types of benign breast disease.

Kate Law, director of clinical research at Cancer Research UK, said: "This landmark study shows that anastrozole could be valuable in helping to prevent breast cancer in women at higher than average risk of disease. We now need accurate tests that will predict which women will most benefit from anastrozole and those who will have the fewest side-effects."

Dr Harpal Kumar, Cancer Research UK's chief executive, said: "Cancer Research UK has been funding the IBIS II trial for more than 10 years. We're delighted that the results will now offer women at high risk of breast cancer a new option to significantly reduce their chance of developing the disease. By supporting large trials such as this, which take a long time to complete, we can make discoveries that will help us to save many more lives in the future."

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...